AP598A - Metronidazole combinations. - Google Patents
Metronidazole combinations. Download PDFInfo
- Publication number
- AP598A AP598A APAP/P/1995/000773A AP9500773A AP598A AP 598 A AP598 A AP 598A AP 9500773 A AP9500773 A AP 9500773A AP 598 A AP598 A AP 598A
- Authority
- AP
- ARIPO
- Prior art keywords
- pharmaceutical unit
- derivatives
- compounds
- cephalosporin
- metronidazole
- Prior art date
Links
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229960000282 metronidazole Drugs 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000004599 antimicrobial Substances 0.000 claims description 19
- 229930186147 Cephalosporin Natural products 0.000 claims description 17
- 229940124587 cephalosporin Drugs 0.000 claims description 17
- 150000001780 cephalosporins Chemical class 0.000 claims description 17
- 150000002960 penicillins Chemical class 0.000 claims description 16
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 12
- 229930182555 Penicillin Natural products 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims description 4
- 206010019375 Helicobacter infections Diseases 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
According to the present invention there is provided a pharmaceutical unit comprising a therapeutically effective amount of metronidazole together
Description
REPUBLIC OF SOUTH AFRICA
3. FREDERIK JOHANNES POTGIETER Plot 2
Kammeeldrift East Pretoria
REPUBLIC OF SOUTH AFRICA
AP . Ο Ο 5 9 8
This *nvention relates to pharmaceutical units which include a plurality of active ingredients.
According to the present invention there is provided a pharmaceutical unit comprising a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of (? compounds and derivatives of Cephalosporin range of compounds.
The at least one other antimicrobial compound may comprise a compound suitable for treating relapse of peptic ulcers.
Preferably, the at least one other antimicrobial θ compound comprises a compound active against θ Helicobacter pylori.
In one embodiment ’of the invention the at least one other antimicrobial compound may comprise a compound of the Cephalosporin range of antibiotics.
In an alternative and preferred embodiment of the
AP/P/ 95/00773 invention the at least one other antimicrobial compound may comprise a penicillin or a derivative thereof.
In the preferred embodiment of the invention the at least one other antimicrobial compound may comprise amoxycillin or a salt thereof. Most preferably the amoxycillin salt comprises amoxycillin trihydrate.
The weight ratio between the metronidazole and amoxycillin trihydrate may be any suitable ratio, but preferably it is approximately 1:1,4375.
The pharmaceutical unit may include one or more additives.
The additives may comprise one or more compounds selected from the group consisting of disintegrants, surface active agents, lubricants and diluents. Preferably it include a disintegrant, a surface active agent, a lubricant and a diluent. The disintegrant may comprise sodium starch glycollate. The surface active agent may comprise sodium lauryl sulphate. The lubricant may comprise talc and the diluent may comprise starch, preferably maize starch.
The pharmaceutical unit may comprise a capsule.
amounts
AP .0 0 5 9 8
The pharmaceutical unit may comprise suitable of metronidazole and the at least one other antimicrobial compound to provide a single dose unit.
According to one specific embodiment of the invention there is provided a pharmaceutical unit including 200mg metronidazole and 287,5mg amoxycillin trihydrate.
According to one aspect of the invention there is provided a pharmaceutical unit substantially as described hereinabove for use in the treatment of infections. The infections may comprise infections of the upper respiratory tract and preferably it comprises gingivitis.
According to another aspect of the invention there is provided a pharmaceutical unit substantially as described hereinabove for use in the treatment of ulcers and preferably the relapse of peptic ulcers. The pharmaceutical unit may also be used pro-actively.
According to another aspect of the invention there is provided a pharmaceutical unit substantially as described hereinabove for use in the treatment against Helicobacter pylori infections.
EZZ00/G6 /d/dV
The invention further relates to the use of a combination of a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for use in the treatment of infections. The infections may comprise infections of the upper respiratory tract and preferably it comprises gingivitis.
The invention also relates to the use of a combination of a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for use in the treatment of peptic ulcers.
The invention further relates to the use of a combination of a therapeutically effective amount of
AP/P/ 9 5 / 0 0 7 7 3
AP . 0 0 5 9 8 metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalasporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for treatment against Helicobacter pylori.
The pharmaceutical unit described hereinabove may be used in combination with an acid suppressant in the treatment of the relapse of peptic ulcers or the effects of Helicobacter pylori on mammals.
The invention will now be further described with reference to the following non-limiting example.
Example
AP/P/ 9 5 / 0 0 7 7 3
A capsules containing metronidazole and amoxycillin trihydrate was formed. The capsule contained the following(ingredients.
Ingredient Mass in mq
1. Metronidazole 200
- 6 Ingredient
Mass in mg
| 2. | Amoxycillin trihydrate | 287,5 |
| 3. | Sodium starch glycollate | 20 |
| 4. | Sodium lauryl sulphate | 4 |
| 5. | Talc | 7 |
| 6. | Maize starch | 131,5 |
| The | metronidazole was put through | a 1mm screen to break |
| up | lumps. Compounds 1, 2 and 6 | were mixed to form a |
| pre | -mix A. Compounds 3, 4 and 5 | were separately mixed |
| to | form a pre-mix B. The pre-mixtures A and B were |
added together and thoroughly mixed and thereafter the capsule was filled.
The inventors believe that it is easier and more convenient to use a unit as described hereinabove instead of the active ingredients provided in separate form. It is also believed that the use of the unit would lead to improved patient compliance.
It will be appreciated that many variations in detail are possible without thereby departing from the scope and spirit of the invention.
Claims (21)
- Πι*{;·,,' r.D'v {;ar’ki; ♦uTtfju’.iJ .T.y/uur : wi-.*i m.Kinrr the in dc.ulii Ih .1 v..•j comprising amount1. A pharmaceutical unit therapeutically effective metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds.a of
- 2. The pharmaceutical unit of claim 1 wherein the at least one other antimicrobial compound comprises a compound suitable for treating relapse of peptic ulcers.
- 3. The pharmaceutical unit of either one of claims 1 or 2 wherein the at least one other antimicrobial compound comprises a compound active against Helicobacter pylori.
- 4. The pharmaceutical unit of claim 1 wherein the at least one other antimicrobial compoundAP/P/ 9 5 / 0 0 7 7 3 comprises a compound of the Cephalosporin range of antibiotics.
- 5. The pharmaceutical unit of claim 1 wherein the at least one other antimicrobial compound comprises a penicillin or a derivative thereof.
- 6. The pharmaceutical unit of claim 5 wherein the at least one other antimicrobial compound comprises amoxycillin or a salt thereof.c
- 7. The pharmaceutical unit of claim 6 wherein the amoxycillin salt comprises amoxycillin trihydrate.
- 8. The pharmaceutical unit of claim 7 wherein the weight ratio between the metronidazole and amoxycillin trihydrate is approximatelyQ 1:1,4375.c
- 9. The pharmaceutical unit of any one of the preceding claims which includes one or more additives.
- 10. The pharmaceutical unit of claim 9 wherein the additives comprise one or more compoundsAP/P/ 95/00773AP. Ο Ο 5 9 8 selected from the group consisting of disintegrants, surface active agents, lubricants and diluents.
- 11. The pharmaceutical unit of claim 10 which includes a disintegrant, a surface active agent, a lubricant and a diluent.
- 12. The pharmaceutical unit of any one of the preceding claims which comprises a capsule.o
- 13. The pharmaceutical unit of any one of the preceding claims which comprises suitable amounts of metronidazole and the at least one other antimicrobial compound to provide a single dose unit.
- 14. The pharmaceutical unit of claim 13 which includes 200mg metronidazole and 287,5mg θ amoxycillin trihydrate.
- 15. A pharmaceutical unit substantially as herein described with reference to the accompanying example.
- 16. A pharmaceutical unit of any one of theAP/P/ 9 5 / 0 0 7 7 3
preceding claims infections. for us :e in the treatment of 17. A pharmaceutical unit of any one of the preceding claims ulcers. for use in the treatment of 18. A pharmaceutical unit of any one of the preceding claims for use relapse of peptic ulcers. in the treatment of the 19. A pharmaceutical unit of any one of the preceding claims for use in the treatment against Helicobacter pylori infections. - 20. The use of a combination of a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for use in the treatment of infections.AP/P/ 9 5 / 0 0 7 7 3ΑΡ. 0 0 5 9 8 ίI ίi
- 21. The use of a combination of a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for use in the treatment of peptic ulcers.
- 22. The use of a combination of a therapeutically effective amount of metronidazole together with a therapeutically effective amount of at least one other antimicrobial compound selected of the group consisting of tetracylines, tetracyline derivatives, penicillins, penicillin derivatives, Cephalosporin range of compounds and derivatives of Cephalosporin range of compounds in the preparation of a medicament in the form of a pharmaceutical unit for treatment against Helicobacter pylori infections.
- 23. The use of any one of claims 20 to 22 wherein the pharmaceutical unit is a unit of any one ofAP/P/ 9 5 / 0 0 7 7 3
- 24. The use of claim 23 wherein the pharmaceutical unit is a unit of any one of claims 6 to 8.claims 1 to 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA9410112 | 1994-12-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9500773A0 AP9500773A0 (en) | 1996-01-31 |
| AP598A true AP598A (en) | 1997-07-21 |
Family
ID=25584684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1995/000773A AP598A (en) | 1994-12-20 | 1995-12-14 | Metronidazole combinations. |
Country Status (2)
| Country | Link |
|---|---|
| AP (1) | AP598A (en) |
| ZA (1) | ZA9510732B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060379A3 (en) * | 2003-01-03 | 2004-10-14 | Marton Milankovits | Pharmaceutical compositions comprising an antibacterial agent nd antifungal agent and a nitroimidazole for the treatment and prevention of genitourinary infections and their extragenital complications |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997830A (en) * | 1990-02-07 | 1991-03-05 | The Research Foundation Of State University Of New York | Pharmaceutical composition for the treatment of periodontitis |
-
1995
- 1995-12-14 AP APAP/P/1995/000773A patent/AP598A/en active
- 1995-12-18 ZA ZA9510732A patent/ZA9510732B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997830A (en) * | 1990-02-07 | 1991-03-05 | The Research Foundation Of State University Of New York | Pharmaceutical composition for the treatment of periodontitis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060379A3 (en) * | 2003-01-03 | 2004-10-14 | Marton Milankovits | Pharmaceutical compositions comprising an antibacterial agent nd antifungal agent and a nitroimidazole for the treatment and prevention of genitourinary infections and their extragenital complications |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA9510732B (en) | 1996-06-20 |
| AP9500773A0 (en) | 1996-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100202154B1 (en) | Film coated tablets containing paracetamol and domperidone | |
| CA2292359A1 (en) | Novel azalides and methods of making same | |
| PT761218E (en) | METHOD FOR PREPARING POLYMER-COATED TABLETS COMPREHENDING AMOXYCYCLINE AND CLAVUNALATE | |
| IE911483A1 (en) | Medicament containing triclosan for treating gastro-intestinal disorders | |
| CZ282352B6 (en) | Pharmaceutical preparation for peroral administration | |
| BG104727A (en) | Pharmaceutical composition of topiramate | |
| GR77915B (en) | ||
| KR930005619A (en) | Drugs for treating gastrointestinal diseases | |
| PE20001297A1 (en) | ANTIBIOTICS CETOLIDES CARBAMATE AND CARBAZATE | |
| SE9901573D0 (en) | New compounds | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| AP598A (en) | Metronidazole combinations. | |
| IL99471A (en) | Pharmaceutical compositions for treating helicobacter bacteria infections containing 5-fluoromethoxy-2-(3,4-dimethoxy-2-pyridyl)methylsulphinyl)-1h-benzimidazole and salts thereof in combination with an antimicrobial agent | |
| FR2500303B1 (en) | ||
| WO2000066550A8 (en) | New compounds | |
| JPH11508566A (en) | Antibacterial synergistic composition containing rifabutin | |
| WO1996019220A1 (en) | A combination product comprising nitazoxanide and an anti-ulcer agent | |
| RU98102187A (en) | APPLICATION OF ALLYLAMINE DERIVATIVES, SUCH AS TERBINAFIN, IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OR ASSOCIATED DISEASES | |
| CA2103787A1 (en) | Use of benzimidazole anthelmintic in the treatment of microsporidial infections | |
| WO1994008594A1 (en) | Pharmaceutical composition containing an antimicrobial agent and an antibiotic | |
| US4871722A (en) | Synergistic veterinary composition and/or fodder premix and process for preparing same | |
| JPH054926A (en) | Sugar-coated tablets containing useful enteric bacteria | |
| JPS554397A (en) | Novel n11benzoylln22phenyll1*33diaminopropane 22ol*its manufacture and medicine containing it for therapy of acute and chronic gastritis | |
| AU621459B2 (en) | Compositions comprising baquiloprim and sulphadimethoxine | |
| JP4081157B2 (en) | Antibacterial agent for Helicobacter pylori |